StockData
BioVie Inc. logo

BioVie Inc. (BIVI) stock

BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$0.94−0.05 (-5.27%)

Close on Nov 18, 2026Market cap $7.11MP/E –Yield –

BioVie operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BioVie's operating income for the twelve months ending Jun 30, 2026 was -$22.65M. For fiscal 2026 it was -$22.65M. The highest annual figure on record is -$233.38K in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$22.65M–
FY2025Jun 30, 2025-$18.07M–
FY2024Jun 30, 2024-$32.18M–
FY2023Jun 30, 2023-$45.08M–
FY2022Jun 30, 2022-$27.25M–
FY2021Jun 30, 2021-$138.05M–
FY2020Jun 30, 2020-$2.69M–
FY2019Jun 30, 2019-$2.50M–
FY2018Jun 30, 2018-$2.37M–
FY2017Jun 30, 2017-$1.55M–
FY2016Jun 30, 2016-$432.03K–
FY2015Jun 30, 2015-$233.38K–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$5.72M–
Q3 FY2026CQ1 2026Mar 31, 2026-$5.39M–
Q2 FY2026CQ4 2025Dec 31, 2025-$6.26M–
Q1 FY2026CQ3 2025Sep 30, 2025-$5.28M–
Q4 FY2025CQ2 2025Jun 30, 2025-$3.66M–
Q3 FY2025CQ1 2025Mar 31, 2025-$2.99M–
Q2 FY2025CQ4 2024Dec 31, 2024-$7.29M–
Q1 FY2025CQ3 2024Sep 30, 2024-$4.12M–
Q4 FY2024CQ2 2024Jun 30, 2024-$4.79M–
Q3 FY2024CQ1 2024Mar 31, 2024-$7.73M–
Q2 FY2024CQ4 2023Dec 31, 2023-$8.78M–
Q1 FY2024CQ3 2023Sep 30, 2023-$10.88M–
Q4 FY2023CQ2 2023Jun 30, 2023-$10.98M–
Q3 FY2023CQ1 2023Mar 31, 2023-$13.77M–
Q2 FY2023CQ4 2022Dec 31, 2022-$11.49M–
Q1 FY2023CQ3 2022Sep 30, 2022-$8.83M–
Q4 FY2022CQ2 2022Jun 30, 2022-$9.29M–
Q3 FY2022CQ1 2022Mar 31, 2022-$5.75M–
Q2 FY2022CQ4 2021Dec 31, 2021-$6.67M–
Q1 FY2022CQ3 2021Sep 30, 2021-$5.55M–
Q4 FY2021CQ2 2021Jun 30, 2021-$131.60M–
Q3 FY2021CQ1 2021Mar 31, 2021-$3.00M–
Q2 FY2021CQ4 2020Dec 31, 2020-$3.06M–
Q1 FY2021CQ3 2020Sep 30, 2020-$386.76K–
Q4 FY2020CQ2 2020Jun 30, 2020-$576.97K–
Q3 FY2020CQ1 2020Mar 31, 2020-$699.25K–
Q2 FY2020CQ4 2019Dec 31, 2019-$710.45K–
Q1 FY2020CQ3 2019Sep 30, 2019-$706.22K–
Q4 FY2019CQ2 2019Jun 30, 2019-$655.99K–
Q1 FY2019CQ3 2018Dec 31, 2018-$992.30K–
Q4 FY2018CQ2 2018Jun 30, 2018-$523.91K–
Q3 FY2018CQ1 2018Mar 31, 2018-$691.22K–
Q2 FY2018CQ4 2017Dec 31, 2017-$494.81K–
Q1 FY2018CQ3 2017Sep 30, 2017-$662.23K–
Q4 FY2017CQ2 2017Jun 30, 2017-$443.93K–
Q3 FY2017CQ1 2017Mar 31, 2017-$400.53K–
Q2 FY2017CQ4 2016Dec 31, 2016-$357.80K–
Q1 FY2017CQ3 2016Sep 30, 2016-$351.35K–
Q4 FY2016CQ2 2016Jun 30, 2016-$269.62K–

More BioVie figures

See a number that looks wrong?